NYU Langone to Drop Sackler Name from Biomedical Institute

The decision comes after Purdue Pharma, founded by the Sackler family, announced it would plead guilty to federal criminal charges for its role in the opioid epidemic.

Written byMax Kozlov
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

ABOVE: © ISTOCK.COM,
CRIBBVISUALS

New York University’s Langone Medical Center will remove the Sackler family name from its Institute of Graduate Biomedical Sciences after the US Department of Justice announced last week (October 21) that Purdue Pharma, founded by the Sackler family, would plead guilty to three criminal charges for its role in the opioid epidemic.

“Given the Sackler family’s association with Purdue Pharma and its role in encouraging opioid overuse, we view continuing to use the Sackler name as inconsistent with our institution’s values and incompatible with our mission,” university officials wrote in a statement, according to the Associated Press.

Purdue, which makes the painkiller OxyContin, will plead guilty to conspiring to defraud the United States and violating federal anti-kickback laws as part of a settlement for more than $8 billion. The deal does not release the company’s executives, nor the Sacklers, from criminal liability, and a criminal investigation is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Max is a science journalist from Boston. Though he studied cognitive neuroscience, he now prefers to write about brains rather than research them. Prior to writing for The Scientist as an editorial intern in late 2020 and early 2021, Max worked at the Museum of Science in Boston, where his favorite part of the job was dressing in a giant bee costume and teaching children about honeybees. He was also a AAAS Mass Media Fellow, where he worked as a science reporter for the St. Louis Post-Dispatch. Read more of his work at www.maxkozlov.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies